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Abstract 
Chinese herbal medicine has been shown to be a potential anti-cancer drug by inducing 
differentiation, apoptosis, inhibiting angiogenesis, reversing multi-drug resistance 
through different mechanisms. Pteris semipinnata L (PsL), a Chinese herb, was 
traditionally used to treat enteritis, hepatitis and snake bites. The natural chemical 
compound ent-11 -hydroxy-15-oxo-kaur-16-en-19-oic-acid (5F), an ethanolic extract of 
PsL, has been shown to carry anti-tumor activity by inducing apoptosis in human colon 
cancer, gastric cancer and thyroid cancer. 
In cancer chemoprevention and chemotherapy, induction of apoptosis is an attractive 
strategy by introducing the anti-cancer drug either orally or injection. Since 5F can 
induce apoptosis as shown by many evidences, it can be employed as a potential 
apoptosis induction drug in laryngeal cancer therapy. Moreover, NF-KB, one of 5F target 
in human colon cancer cells, is one of the most important apoptosis regulators. Because 
N F - K B activity was increased in laryngeal cancer, its role in 5F-induced apoptosis might 
be pivotal. On the other hand, there are growing evidences showing that HPV was 
associated with laryngeal carcinogenesis. How 5F functions in HPV positive or negative 
laryngeal cancer cells is unknown. 
In this project, three laryngeal cancer cell lines, UMSCCllA, UMSCC12 and HEp-2, 
were employed. HEp-2 is HPV 18 positive while the others are HPV 18 negative. Our 
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results demonstrated that 5F inhibited laryngeal cancer cell growth in a does-dependent 
manner. It was noticed that HEp-2 was more resistant to 5F. E6 and E7 (encoded by 
HPV18) were reported to promote cell growth; therefore, it is conceivable that the 
presence of HPV18 may account for the resistance to the anti-proliferation of 5F of the 
HEp-2. We found that 5F suppressed the expression of E7 while the expression of E6 
was not altered. Cleavage of pro-caspase 3 and poly (ADP-ribose) polymerase (PARP) 
and Annexin V assay confirmed that 5F induced apoptosis in laryngeal cancer cells. 
Moreover, 5 F suppressed the N F - K B activity, via blockage of N F - K B nuclear 
translocation, leading to inhibition of its target gene products responsible for cell 
proliferation and apoptosis. With the results shown by N F - K B specific inhibitor, Bay 
(11-7082)，we verified that N F - K B is responsible for laryngeal cancer cell survival. 
In conclusion, we demonstrated that suppression of N F - K B activity involved in 
5F-induced apoptosis in laryngeal cancer cells. This implicated that 5F may represent as 
a new potent agent, or in combination with other inhibitors, for treatment of laryngeal 
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Chapter One General Introduction 
1.1 Background 
Head and neck squamous cell carcinoma (HNSCC) has high incidence and mortality rate 
particularly in Southeast Asia and Eastern Europe (Franceschi et al. 1996) while 
laryngeal squamous cell carcinoma is the most common type of HNSCC worldwide 
(Jemal et al. 2006). It is more common in men than in women. When incidence and 
mortality are compared by gender, it was found that by 2005, the worldwide incidence 
of laryngeal carcinoma in male and female was 139,230 vs. 20,011 while the mortality 
was 78,629 in male and 11,327 in female (Parkin et al. 2005). Besides, the incidence of 
laryngeal carcinoma is also increasing. The global cancer statistics for laryngeal 
carcinoma reported 159,000 new cases and estimated 90,000 deaths in 2002. The latest 
report on cancer statistics in the United States of America estimated that 9680 men and 
2570 women had laryngeal carcinoma as well as 2910 men and 760 women died due to 
the cancer in 2008 (Jemal et al. 2008). 
Hong Kong is a high risk area for laryngeal cancer in terms of the incidence rate 
(Syijanen 2005). In between 2000 and 2005, averagely 14 and 185 new cases of 
laryngeal carcinoma in women and men were reported respectively in each year 
(Hospital Authority: Hong Kong Cancer Registry). Due to the increasing incidence and 
mortality rate of laryngeal carcinoma, even though the patient population is not large 
worldwide or in Western Countries, more attention still need to paid for the development 
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of laryngeal carcinoma detection and treatment in Southeast Asia and in Hong Kong. 
Multiple causative factors have been implicated in the development of laryngeal 
squamous cell carcinoma (SCC). Most of them are related to tobacco products and 
alcohol consumption, oral hygiene, health, lifestyle, sunlight exposure, age, and gender 
(Uobe et al. 2001). Among these, tobacco smoking, alcohol consumption and betel 
chewing are major risk factors of HNSCC. Heavy smokers and drinkers have a 17.6 fold 
and a 79.6 fold increased risk of laryngeal carcinoma respectively when compared with 
non-smokers and light drinkers (Franceschi et al. 1990). 
However, a small proportion of HNSCC individuals do not have any history of tobacco 
or alcohol use, suggesting the presence of other possible causes of the cancers. One of 
the possible causes is the human papillomavirus (HPV) infection (anal, vaginal and 
vulvar), which is associated with an increased risk of developing tumours. Women with 
a history of in situ (Bjorge et al. 1995) or invasive cervical cancer (Boice et al. 1985; 
Rabkin et al. 1992) have a 2 to 4 fold increased risk of developing oral or laryngeal 
cancer. 
1.2 Human papillomavirus infection at the larynx 
Larynx is the most common site for HPV infection, which commonly causes laryngeal 
papillomatosis or recurrent respiratory papillomatosis (RRP) (Syijanen 2005). While the 
HPV viral aetiology of cervical cancer is well-characterized (Walboomers et al. 1999)， 
its role in the larynx was first described by Ullman (Ullman UV 1923). The supercoiled 
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viral DNA was first identified by Crawford and Crawford (Crawford and Crawford 
1963). Later, the existence of different types of HPV was demonstrated and more than 
90 HPV types have been characterized (Syijanen et al. 1987; Herrero 2003; Chen et al. 
2005). The virus types can be classified into high-risk (HPV 16，18，31 and 45), 
intermediate risk (HPV 33，35，39 and others) and low-risk (HPV 6 and 11) types, based 
on their epidemiologic association with cancer and benign epithelial hyper-proliferation 
(zur Hausen 1996). The observed roughly 80% prevalence of HPV in RRP is almost as 
high as in cervical cancer, which is a well-established HPV associated-disease (Derkay 
and Darrow 2000). While these lesions are basically benign, malignant transformation 
into laryngeal SCC does occur in a certain proportion of cases. Combining its high 
prevalence in RRP with its malignant potential, HPV may be associated with the 
development of laryngeal carcinoma. 
The role of HPV in laryngeal carcinoma has been suggested by the detection of typical 
cytopathic effects of HPV in these lesions (Syijanen and Suijanen 1981). The most 
convincing evidence that implicates HPV in laryngeal cancer is derived from studies 
demonstrating the presence of HPV DNA in cancer lesions. In a systematic review by 
Kreimer, 24% of the samples were reported to be HPV positive in 1435 larynx SCC 
specimens from 18 countries and 35 studies. Of the HPV positive larynx SCC, HPV 16 
was the most common type with a 69.2% prevalence rate while HPV 18 accounted for a 
17% prevalence rate (Kreimer et al. 2005). It is currently suggested that the high risk 
HPV 16 and 18 are responsible for a subset of laryngeal carcinoma although the reported 
HPV DNA detection rates varied widely (Syijanen and Puranen 2000; Herrero 2003). 
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1.2.1 Biology of human papillomavirus 
Human papillomavirus is a small non-enveloped DNA virus with a virion the size of 
~55nm in diameter (Zheng and Baker 2006). HPV replicates and assembles exclusively 
in the nucleus of the host cell. All HPVs contain a double-stranded, circular DNA 
genome approximately 8kb in size that can be divided into three major regions: early, 
late and a long control region (LCR, a noncoding region). The genome of the early 
region occupies over 50% of the virus genome and encodes six proteins (El, E2, E4, E5, 
E6 and E7). El and E2 are involved in the replication of the viral genome and interact 
with the host cell intermediate filament E4. The function of the E3 gene is unknown. E5, 
E6 and E7 are viral oncoproteins which induce cell immortalization and transformation. 
In particular, E6 and E7 inactivate two cellular tumor suppressor proteins p53 and pRb 
respectively (Gamett and Duerksen-Hughes 2006). Moreover, the E2 protein is a 
transcriptional repressor of E6 and E7 gene expression. As the integration of HPV DNA 
into the host genome results in deletion of part of the virus genome, loss of E2 was 
thought to result in the over-expression of E6 and E7 (Tan et al. 1994; Corden et al. 
1999). The late region covers almost 40% of the virus genome and encodes LI and L2 
open reading frame for translation of a major (LI) and minor (L2) capsid protein. The 
LCR region, a segment of about 850bp, does not encode any protein but plays a role in 
the origin of replication as well as in multiple transcription factor binding sites. As the 
E6 and E7 proteins of the high risk (HR) HPV play a pivotal role in cell proliferation, 
viral replication and circumvent host-mediated apoptosis, many studies focus on the 
roles of these two proteins in carcinogenesis. 
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1.2.2 HPV E6 protein 
E6 plays crucial roles in the HPV viral life cycle, as well as in cellular transformation 
and immortalization (Bedell et al. 1989). It is about 150 amino acids in size and is 
expressed in two forms: a flill-length version of 16kDa and a truncated form about half 
that size corresponding to the N-terminal half of the full-length protein (Mantovani and 
Banks 2001). Two zinc fingers are composed of four Cys-X-X-Cys (X representing any 
amino acid) motifs which are responsible for E6 function (Cole and Danos 1987; 
Barbosa et al. 1989). HR HPV E6 protein contains a highly conserved five amino acids 
C-terminal domain which mediates direct binding to PDZ proteins. PDZ domain 
proteins serve critical roles in various molecular processes including cell polarity and 
signal transduction. The binding of E6 and PDZ proteins is clearly important for HPV 
associated carcinogenesis, because deletion of the relevant domain inhibits E6 driven 
transformation in rodent cells (Kiyono et al. 1997) and epithelial hyperplasia in mice 
(James et al. 2006). Further, the expression of the E6 protein results in activation of the 
telomerase reverse transcriptase (TERT) promoter allowing for increased telomerase 
activity and extension of the cellular life-span through elongation of the telomeric 
repeats (Klingelhutz et al. 1996). 
The first identified and best characterized E6 interacting partner is tumour suppressor 
p53 (Wemess et al. 1990). The p53 transcription factor is the most frequently inactivated 
tumour suppressor gene in human cancer and is involved the control of cell proliferation 
in response to stress. Under normal physiological conditions, the p53 protein level is 
very low. In the early stages of HR HPV infection, E7 oncoprotein induces a significant 
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increase in cell proliferation as a result of its interaction with the protein retinoblastoma, 
which triggers the expression of p53 (Longworth and Laimins 2004). In the absence of 
E6, the rise in p53 levels would lead to cell cycle arrest and/or apoptosis. However, the 
case is completely different in the presence of E6. E6 binds to p53 with the aid of 
E6-associated protein (E6-AP) ligase and prevents p53 from inducing growth arrest and 
apoptosis by subjecting it to ubiquitin-proteasome degradation pathway (Huibregtse et al. 
1991). Moreover, E6 also precludes the growth-suppressive activities of p53 by 
cytoplasmic sequestration and by transcriptional suppression of its target genes 
(Mantovani and Banks 2001). 
There are a number of proteins other than p53 targeted by E6. These proteins involve in 
regulation of transcription (Zimmermann et al. 1999), DNA replication (Gao et al. 1999), 
apoptosis and immune evasion (Gross-Mesilaty et al. 1998; Thomas and Banks 1998)， 
epithelial organization and differentiation (Tong and Howley 1997), cell-cell adhesion 
and proliferation control (Thomas et al. 2001), and DNA repair (Srivenugopal and 
Ali-Osman 2002). 
Of the proteins involved in apoptosis, it was found that E6 inhibits Bak-mediated 
apoptosis by directly binding to Bak, an interaction which is conserved in high risk and 
low risk HPVs (Thomas and Banks 1998; Thomas and Banks 1999). In our laboratory, 
E6 was found to inhibit TNF-mediated apoptosis by reducing the expression of Bak and 
increasing Bcl-2 expression without significantly affecting the expression of caspase-3 
and -8 in laryngeal cancer cells (Du et al. 2004). 
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1.2.3 HPV E7 protein 
HR HPV E7 protein, small dimerized phosphoprotein, is approximately 100 amino acids 
in size with three conserved regions: CRl, CR2 and CR3, which are critical for viral 
oncogenic activities (Wise-Draper and Wells 2008). There is a Leu-X-Cys-X-Glu motif 
within CR2 that mediates the binding with retinoblastoma (Rb) protein family, and is 
also necessary for viral DNA maintenance during the infectious cycle (Dyson et al. 1989; 
Munger et al. 1989; Datto et al. 1995). The CR3 region located at the C-terminus 
consists of a metal binding domain composed of two Cys-X-X-Cys motifs separated 
from each other by 29 amino acids. The C-terminal zinc-binding regions are important 
for E7 protein structure including dimerization (Clemens et al. 1995; Clements et al. 
2000), intracellular stabilization (Edmonds and Vousden 1989; Phelps et al. 1992)，as 
well as for the formation of high-molecular mass oligomers with apparent chaperone 
holdase activity (Alonso et al. 2006). Many cellular interacting partners for E7 have 
been identified, but the biological significance for most of the observed interactions 
remains to be explored. 
What have been intensively studied are the Rb, pi07 and pi30，members of the 
retinoblastoma family, which are the targets of the E7 protein (Dyson, Howley 1989; 
Berezutskaya et al. 1997). Both low and high risk E7 can interact with Rb, however, the 
relative Rb binding affinities are 10 fold higher in high risk E7 than in low risk E7 
(Munger et al. 1992). Rb has an important role in the suppression of cellular 
proliferation (Cobrinik 2005), stimulation of differentiation and senescence (Deshpande 
et al. 2005; Dimri 2005)，cell survival (Chau and Wang 2003) and the maintenance of 
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stem cell quiescence (Ruiz et al. 2004). Normally, Rb forms a complex with histone 
deacetylase (HDAC) and binds to the E2F transcription factor in the G1 phase of the cell 
cycle. This prevents E2F from transactivating genes that are necessary for proliferation 
until the cell enters the S phase. However, the mechanism is different when E7 is 
expressed in cells. E7 binds to the complex of Rb and HDAC and relieves their 
repression of E2F, resulting in the constitutive activation of repression genes. 
Consequently, E7 provokes the cell to re-enter the S phase, where cellular replication 
factors required for viral replication are activated. 
E7-Rb interactions are not sufficient for the abrogation of cell cycle arrest. Such activity 
also requires the binding of E7 and the proteins involved in cell cycle control such as 
cyclin-dependent kinase cdk2 and cyclin A (Tommasino et al. 1993)，proteins regulating 
transcription such as the TATA box-binding protein and transcription factors API 
(Antinore et al. 1996), and proteins for other cellular functions such as TAF-110 and 
TBP (Mazzarelli et al. 1995). 
In addition to its role in cell proliferation and viral replication, E7 also regulates 
apoptosis. However, it has dual effects on cellular apoptotic pathways. It was reported 
that the expression of E7 in fibroblasts delayed Fas-mediated apoptosis and prevented 
TNF-mediated apoptosis by suppression of caspase-8 activation (Thompson et al. 2001). 
On the other hand, the majority of studies suggest that E7 serves a pro-apoptotic role. In 
a recent study, E7 was shown to inhibit TNF-mediated apoptosis in keratinocytes by 
up-regulating the expression of the inhibitor of the apoptosis protein C-IAP2 (Yuan et al. 
2005). Moreover, E7 has been shown to sensitize mouse lymphoma cells (JD3) to 
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IFN-a-induced apoptosis (Thyrell et al. 2005), co-express with p21 and induce apoptosis 
in U20s osteosacroma cells (Kaznelson et al. 2004)，and over-express in genital 
keratinocytes which induces spontaneous cell death and sensitization to TTSfF-mediated 
apoptosis (Stoppler et al. 1998). 
1.3 Apoptosis 
One way to kill cancer cells is by inducing the process of programmed cell death called 
apoptosis. 
Apoptosis in cancer cells can be induced by a number of triggers as diverse as hypoxia, a 
shortage of nutrients or growth factors, and radiotherapy or chemotherapy. Apoptosis is 
different from necrosis, which is usually immunologically harmful due to the sudden 
release of proinflammatory mediators (Vakkila and Lotze 2004). Necrosis is 
morphologically characterized by swelling of the cytoplasm, leading to the rupture of the 
plasma membrane, and the release of swollen and damaged organelles. Necrotic cell 
death often causes the release of proinflammatory cytokines, such as interleukin-8, IL-10, 
TNF-a (Fadok et al. 2001), or of terminal mediators of inflammation, such as 
high-mobility group boxl (Wang et al. 1999; Scaffidi et al. 2002). 
During the early stage of apoptosis, cell shrinkage and pyknosis are the two visible 
morphological changes under the light microscopy (Kerr et al. 1972). With cell 
shrinkage, the cells become smaller in size; the cytoplasm is dense and the organelles are 
more tightly packed. Pyknosis is the result of chromatin condensation and is the most 
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characteristic feature of apoptosis. Apoptotic cell appears as a round or oval masses with 
dark eosinophilic cytoplasm and dense purple nuclear chromatin fragments. Extensive 
plasma membrane blebbing occurs followed by karyorrhexis and separation of cell 
fragments into apoptotic bodies that consist of cytoplasm with tightly packed organelles. 
Because the apoptotic bodies are subsequently phagocytosed by macrophages and 
degraded within phagolysosomes, there is no inflammatory reaction associated with the 
process of apoptosis. The cells are rapidly phagocytosed by surrounding cells, 
preventing secondary necrosis, and the engulfing cells do not produce anti-inflammatory 
cytokines (Savill and Fadok 2000; Kurosaka et al. 2003). 
Biochemically, apoptosis is initiated by the cleavage of pro-caspase-3. Cleaved 
caspase-3 induces DNA fragmentation, cross-linking of proteins, degradation of 
cytoskeletal and nuclear proteins, formation of apoptotic bodies, expression of ligands 
for phagocytic cell receptors and finally uptake by phagocytic cells (Hengartner 2000). 
In addition to two major apoptotic pathways, the extrinsic (death receptor pathway) and 
the intrinsic (mitochondrial pathway), there is another pathway induced via either 
granzyme B or granzyme A. All three pathways converge on the same terminal or 
execution pathway. The granzyme A pathway activates a parallel, caspase-independent 
cell death pathway through the damage in single stranded DNA (Martinvalet et al. 2005). 
Caspases are widely expressed in an inactive proenzyme form and have proteolytic 
activity to cleave proteins at aspartic acid residues, involving recognition of neighboring 
amino acids. Ten major caspases have been identified and are broadly categorized into 
initiators (caspase-2,-8,-9,-10), executioners (caspase-3,-6,-7) and inflammatory 
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caspases (caspase-1,-4,-5) (Cohen 1997; Rai et al. 2005). Extensive protein cross-linking 
is another characteristic, achieved through the expression and activation of tissue 
transglutaminase (Nemes et al. 1996). DNA breakdown by Ca^^-and Mg^^-dependent 
endonucleases also occurs, resulting in DNA fragments with 180 to 200 base pairs. 
Expression of cell surface markers results in the early phagocytic recognition of 
apoptotic cells by adjacent cells and phagocytosis with minimal compromise to the 
surrounding tissue. This is achieved by the movement of phosphatidylserine from the 
inner membrane to the outer layer (Bortner et al. 1995). 
1.3.1 Apoptosis signaling pathways 
Two major pathways are involved in the signaling of apoptosis: the death receptor 
mediated extrinsic pathway and the non-receptor mediated intrinsic pathway. 
The extrinsic pathway initiates apoptosis through transmembrane receptor-mediated 
interactions. These involve death receptors that are members of the TNF receptor gene 
superfamily (Locksley et al. 2001). There is a death domain, located in the cytoplasm, 
responsible for transmitting the death signal from the cell surface to the intracellular 
signaling pathways (Ashkenazi and Dixit 1998). To date, the best-characterized ligands 
and corresponding death receptors include FasL/FasR, TNF-a/TNFRl, Apo3L/DR3, 
Apo2L/DR4 and Apo2L/DR5 (Chicheportiche et al. 1997; Ashkenazi and Dixit 1998; 
Peter and Krammer 1998; Suliman et al. 2001; Rubio-Moscardo et al. 2005). FasL/FasR 
and TNF-a/TNFRl are the best characterized models to elaborate the extrinsic pathway. 
The binding of Fas ligand and receptor results in the binding of adapter protein 
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Fas-associated death domain (FADD), while the binding of TNF ligand to TNF receptor 
results in the binding of the adapter protein TNF-receptor-associated death domain 
(TRADD) with recruitment of FADD and receptor inactive protein (RIP) (Hsu et al. 
1995; Wajant 2002). After that, FADD associates with pro-caspase-8 via dimerization of 
the death effector domain, forming a death-inducing signaling complex (DISC), leading 
to the auto-catalytic activation of pro-caspase-8 and the apoptosis is triggered (Kischkel 
et al. 1995). 
The intrinsic pathway involves a variety of non-receptor-mediated stimuli, including 
growth factors, hormones, cytokine, radiation, toxins, hypoxia and viral infections, that 
produce intracellular signals targeting mitochondrial. Upon stimulation, the inner 
mitochondrial membrane is changed resulting in opening of the mitochondrial 
permeability transition (MPT) pore and loss of the mitochondrial transmembrane 
potential followed by the release of two main groups of normally sequestered 
pro-apoptotic proteins from the intermembrane space into the cytosol (Saelens et al. 
2004). The first group of proteins includes cytochrome c, second mitochondrial activator 
of caspases (Smac), direct lAP (inhibitors of apoptosis proteins) binding protein with 
low PI (DIABLO) and serine protease HtrA2/0mi, which binds and activates Apaf-1 as 
well as pro-caspase-9 and inhibits lAP activity (Du et al. 2000; Schimmer 2004; Garrido 
et al. 2006). The release of a second group of proteins is a late event that occurs after the 
cell is committed to die. It includes pro-apoptotic proteins, apoptotic inducing factor 
(AIF), endonuclease G and caspase activated DNase (CAD). AIF translocates into the 
nucleus and cleaves the DNA into 50-300kb fragments and condensates peripheral 
nuclear chromatin (Joza et al. 2001). Endonuclease G can cleave nuclear chromatin to 
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produce oligonucleosomal DNA fragments (Li et al. 2001). Both AIF and endonuclease 
G are caspase-independent while CAD is cleaved by caspase-3 in order to cut the DNA 
and condensate the chromatin (Enari et al. 1998). 
The control and regulation of these apoptotic mitochondrial events occurs through 
members of the B-cell lymphoma protein 2 (Bcl-2) family proteins which are regulated 
by tumor suppressor protein p53 (Cory and Adams 2002). To date, 25 Bcl-2 family 
members, either pro-apoptotic or anti-apoptotic, govern the mitochondrial membrane 
permeability. It is believed that Bcl-2 family proteins are mainly activated through the 
regulation of cytochrome C release from the mitochondria via alteration of 
mitochondrial membrane permeability. 
Both the extrinsic and intrinsic pathways end at the point of execution, considered as the 
final pathway of apoptosis. Execution caspases activate cytoplasmic endonuclease, 
which degrades nuclear material, and proteases that degrade the nuclear and cytoskeletal 
proteins. Caspase-3, -6 and -7 function as executioner caspases responsible for cleaving 
various substrates including cytokeratins, poly(ADP-ribose) polymerase (PARP), the 
plasma membrane cytoskeletal protein alpha fodrin, the nuclear mitotic apparatus 
protein (NuMA) and others, that ultimately cause the morphological and biochemical 
changes (Slee et al. 2001). 
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1.4 Transcription factor: Nuclear factor - KB 
The nuclear factor-kappaB (NF-KB) pathway is known to be one of the most important 
cellular signaling transduction pathways involved in apoptosis. Also, N F - K B regulates 
other biological functions such as immune function, differentiation, inflammation, stress 
response, and cell survival. NF-KB is constitutively activated in many human cancer 
cells including pancreatic caner (Li et al. 2004), breast and prostate cancer (Nakshatri et 
al. 1997; Shukla et al. 2004)，gastric carcinoma and head and neck squamous cell 
carcinoma (Allen et al. 2007; Levidou et al. 2007), suggesting that N F - K B activation 
plays an important role in cancer development. Thousands of experimental studies have 
shown that down-regulation of N F - K B activity by natural and synthetic inhibitors 
suppresses the development of carcinogenesis, inhibits the growth of cancer cells, and 
induces apoptosis with alteration of gene expression which is critical for the control of 
cancer progression and cancer cell survival. Therefore, it is becoming obvious that 
inhibition of N F - K B activity is highly desirable in the prevention and treatment of cancer 
and, as such, the chemopreventive agents that are known to down-regulate the activity of 
N F - K B could potentially inhibit the development and progression of cancers. 
1.4.1 Overview of the N F - K B signaling pathway 
In mammalians, transcription factor N F - K B is a five member family consisting of homo-
and heterodimers, p65 (RelA), RelB, c-Rel，p50 and p52, and respectively encoded by 
the rela, relb, rel, nfkbl and nfkbl genes (Gilmore 2006). These proteins are 
characterized by the presence of a conserved 300 residue homologous domain near the N 
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terminus (Baldwin 1996; Ghosh et al. 1998). This domain, called the Rel Homology 
domain (RHD), is responsible for dimerization, DNA binding, inhibitor binding and 
nuclear localization (Huxford et al. 1999). On X-ray crystal structure analysis, the RHD 
is composed of two-folded domains linked by a short polypeptide (Ghosh et al. 1995). 
In the resting status, N F - K B is bound by inhibitor KB (IKB) proteins and hence 
sequestered in the cytoplasm as an inactive form. There are seven IKB family members, 
k B a , IKBP, iKBy, IKBE, BC1-3, pi05 (p50 precursor protein) and pi00 (p52 precursor 
protein), which are Ankyrin Repeat Domain (ARD) containing super-family. The IKB 
kinase (IKK) complex (containing two kinase subunits: IKKa and IKKp； one regulatory 
subunit: IKKy) is responsible for the phosphorylation of IKB proteins. Two major 
signaling pathways have been characterized for the activation of N F - K B (Bonizzi and 
Karin 2004). In the canonical (classic) pathway of N F - K B activation, for example, upon 
stimulation by the proinflammatory cytokine tumor necrosis factor a (TNFa), signaling 
pathways lead to activation of the IKB kinase P (IKK) complex, which then 
phosphorylates IKB proteins on two N-terminal serine residues. In the non-canonical 
(alternative) pathway, IKKa is activated by N F - K B inducing kinase and phosphorylates 
the p52 precursor protein pi00 (Senftleben et al. 2001). Phosphorylated IKBS are 
recognized by the ubiquitin ligase machinery, leading to the process of 
polyubiquitination and subsequent degradation, or in the case of pi00，by proteasome 
(Karin and Ben-Neriah 2000). The N F - K B dimers are free to translocate to the nucleus 
and bind to specific sequences in the promoter or enhancer regions of target genes. 
Activated N F - K B can then be down-regulated through multiple mechanisms including 
negative feedback by newly synthesized IKB proteins which bind to and export N F - K B to 
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the cytosol. 
Another pathway that can lead to N F - K B activation is based on activation of casein 
kinase 2 (CK2), instead of IKK, which induce IKB(X degradation through the 
phosphorylation of carboxy-terminal sites. However, this pathway has only a minor role 
in physiological N F - K B activation. It might contribute to skin carcinogenesis because it 
is activated by ultraviolet radiation (Kato et al. 2003). 
1.4.2 Regulation of N F - K B signaling 
Given N F - K B ' S critical involvement in so many physiological responses, the regulation 
of N F - K B signaling is extremely important in response to diverse stimuli that can trigger 
distinct cellular responses in particular physiological contexts. 
Without stimulation, N F - K B transcription factor exists in either homodimer or 
heterodimers in cytoplasm. The structure for dimerization, which is responsible for 
different stimuli, is regulated by the folding of amino acid side chains. The C-terminal 
Ig-like domain of approximately 100 amino acids within the RHD is completely 
responsible for dimer formation. In most N F - K B dimers, but not the RelB homodimer, 
each monomer contributes symmetrical P-strand elements that pack against each other to 
form a p-sheet dimer interface (Huang et al. 1997). The amino acid residues at the dimer 
interface are highly conserved and contribute to dimerization by the positive and 
negative energetic interaction across each member of N F - K B proteins (Hart et al. 2001). 
From studies of many cell types, the p50: RelA heterodimer is more abundant than the 
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RelA:RelA homodimer, with abundance of the cRehcRel homodimer and p50:cRel 
heterodimer being intermediate. However, relative expression levels of N F - K B proteins 
and the abundance of different dimers are dependent on the cell type and cellular context 
in history (Hoffmann et al. 2006). 
On stimulation, two major pathways are triggered, leading to different responses. There 
is a variety of stimuli that can activate the classical pathway: pro-inflammatory stimuli 
and genotoxic, including TNF and interleukin l(IL-l) (Osbom et al. 1989); bacterial 
cell-wall components, such as lipopolysaccharide (LPS) (Sen and Baltimore 1986); 
viruses, such as Rabies virus (Nakamichi et al. 2005); and DNA damaging agents, such 
as doxorubicin. On the other hand, the alternative pathway can be induced by the 
ligation of certain groups of TNF family members including LipR and B cell activating 
factor receptor (BAFFR) (Claudio et al. 2002). 
Although both pathways can affect tumor development (the role of N F - K B on tumor 
progression will be discussed in next section), most of our current knowledge relates to 
the pro-carcinogenic functions of the classical pathway. In alternative pathways, the 
IKKct subunit has a negative-regulatory role by phosphorylating the NF-KB subunits 
RelA and cRel on sites that accelerate their nuclear turnover, leading to termination of 
the NF-KB-mediated gene-induction response. (Lawrence et al. 2005) 
In response to diverse stimuli, different N F - K B dimers are activated to translocate to the 
nucleus and to bind to the specific target genes. The binding between N F - K B and target 
genes is tightly controlled since it directly links to the consequent cellular response. The 
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DNA sequences that specifically bind to N F - K B dimers are collectively known as KB 
sites. Most KB sites appear to be lObp in length with the consensus sequence 5'-GGGRN 
W YYCC-3，(where R represents a purine base, N represents any base, W represents an 
adenine or thymine and Y represents a pyrimidine base) (Sen and Baltimore 1986; Chen 
and Ghosh 1999). The conformations of the KB DNA sites exhibit global structural 
likeness in their protein-bound forms. The DNA is slightly bent towards the major 
groove and the extent of bending is directly correlated to the length of the central tract of 
AT base pairs. The AT-rich sequence is known to possess a higher propensity for 
bending, with longer stretches being more prone to bending. This region of the DNA 
also makes far fewer direct contacts with the protein and the bending seems to facilitate 
N F - K B binding at the flanking recognition sequences (Huang et al. 2005). Both 
monomers of the N F - K B dimers will bind to the D N A sequences with different numbers 
of bp. Each N F - K B has some preference for a specific set of KB sites and some N F - K B 
dimers bind to most KB sites with reasonably high affinities. Through the X-ray 
structures of the different combinations of N F - K B dimers, it is revealed that the p50 and 
p52 subunits bind to the 5bp 5'-GGGRN-3' half-site of the consensus sequence and that 
the RelA, cRel and RelB subunit prefers the 4bp 5'-YYCC-3' half-site (Chen et al. 
2000). The N F - K B interactions with its cognate D N A binding sites are very transient and 
have different affinities, implying a fast dissociation rate constant. In addition, the 
transcriptional control involves the coordinated function of many proteins, including 
DNA-bound transcription factors, co-activators and co-repressors in the context of 
nucleosomal chromatin. It has been shown that large number of proteins located on 
DNA regulatory sequences, protein-protein interactions, are likely to be as important as 
transcription factor-DNA interactions in determining transcriptional specificity. 
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The transcriptional regulation by the NF-KB signaling module is highly sophisticated 
and requires integration of different mechanisms that can generate specificity: 
dynamically control each member of the family of N F - K B dimers, interact with N F - K B 
and KB sites, and alternate conformations of the resulting NF-KB-KB DNA complex 
allowing for alternate co-activator interactions. 
1.4.3 Roles of N F - K B in cancers 
N F - K B is a key regulator for the expression and function of a number of genes involved 
in tumourigenesis. 
N F - K B has dual roles in the regulation of apoptosis in cancer cells. In RelA-/- knockout 
mice, there is massive hepatic apoptosis (Beg et al. 1995). Liver apoptosis has been 
shown to be TNF-a signal dependant in the developing liver, as crossing RelA-/- mice 
with either TNF-a-/- or TNFR-/- mice rescued this liver phenotype (Doi et al. 1999; 
Alcamo et al. 2001). Activation of N F - K B can abrogate TNF-a apoptotic activity 
because N F - K B targets genes encoding for inhibitors of caspase activation and apoptosis. 
Moreover, N F - K B also regulates the anti-apoptotic proteins including I A P I and 2 , 
X-linked lAP, survivin, cellular fas-associated death domain-like IL-1 P-converting 
enzyme inhibitory protein (cFLIP), Bcl-xL, Al , TNF receptor associated factor 1 
(TRAFl) and TRAF2 (Kucharczak et al. 2003). lAPs (c-IAPl, C-IAP2, and XIAP) 
suppress the apoptosis induced by both extrinsic and intrinsic pathways through direct 
inhibition of effector caspases (caspases-3, -6，and -7) (Deveraux et al. 1998). C-FLIP 
shares a high level of homology with pro-caspase-8 without catalytic activity. On 
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induction, c-FLIP associates with TNFR to compete with and block caspase-8 activation 
(Kreuz et al. 2001). Bcl-xL and Al prevent the release of cytochrome c and subsequent 
caspase-9 activation (Kucharczak et al. 2003). T R A P proteins serve to amplify N F - K B 
activation and to interfere with the caspase cascade at the TNFRl level (Luo et al. 2005). 
In addition, N F - K B may inhibit prolonged c-Jun-N-terminal kinases (JNK) activation 
and the accumulation of reactive oxygen species (ROS) in order to block apoptosis. In 
fact, the effect of N F - K B on apoptosis is mostly dependent on the stimulus, cell-type, 
and the involved subunits (Sharma and Narayanan 1996) . N F - K B contributes to cell 
death by transcriptionally up-regulating its pro-apoptotic target genes such as Fas/CD95, 
FasL, death receptor 4 (DR4) and DR5 (Wiener et al. 2004). Another pro-apoptotic 
mechanism involves p 100，carrying death domain in the C-terminus, which mediates the 
recruitment of pi00 to death receptors, such as TNFRl and Fas, leading to caspase-8 
activation before apoptosis (Wang et al. 2002). 
N F - K B plays an important role in tumor invasion and metastasis by regulating 
angiogenic factors such as matrix metalloproteinase 2 (MMP2), MMP9 and serine 
protease urokinase-type plasminogen activator (uPA) (Novak et al. 1991; Rangaswami 
et al. 2004). Transfection of high metastatic human melanoma variant cells with a 
dominant-negative mutant IicBa shows inhibition of tumor growth and prevents lung 
metastasis in nude mice (Huang et al. 2000). In addition, N F - K B also regulates the 
expression of intercellular adhesion molecule 1 and vascular cell-adhesion molecule 1, 
the secretion of chemokines (monocyte chemoattractant protein-1, IL-8), growth factors 
(TNF, VEGF) and cyclooxygenase 2 (COX-2) and epidermal growth factor receptor 
(EGFR) (Loch et al. 2001). 
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N F - K B promotes cell cycle progression by regulating the expression of target genes 
involved in the cell cycle machinery such as cyclin Dl，D2, D3, E and c-myc. The D 
family of cyclins in complexes with the catalytic subunits cyclin-dependent kinases 
(CDK4) and CEK6 are the main regulators required for entry and passage through G1 
phase (Guttridge et al. 2000; Hinz et al. 2001; Hsia et al. 2002). 
1.5 Pteris semipinnata L extract: ent-ll-hydroxy-15-oxo-kaur-16-en-19-oic-acid 
(5F) 
Natural product is an infinite source for remedies for long time and certain diet-derived 
substances can be used to prevent cancer or delay its onset has currently elicited 
considerable interest. 
Many evidences have shown Chinese herbal medicine could be a potential anti-cancer 
drug by inducing differentiation, apoptosis, inhibiting angiogenesis, reversing multi-drug 
resistance through different mechanism (Ruan et al. 2006). Pteris semipinnata L, a 
Chinese traditional herb, was traditionally used to treat enteritis, hepatitis and snake 
bites. The natural chemical compound ent-11 -hydroxy-15-oxo-kaur-16-en-19-oic-acid 
(5F), an ethanolic extract of PsL, has been shown to carry anti-tumor activity by 
inducing apoptosis. 
In human gastric cancer, 5F induced DNA fragmentation and reduction of mitochondrial 
membrane potential, resulting in cell apoptosis through the translocation of Bax from 
cytosol to mitochondria in a p53-dependent manner (Liu et al. 2005A). In addition, it 
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was found that 5F induced thyroid cancer cell apoptosis in time- and dose- dependent 
manner by the activation of c-Jun N-terminal kinase and the rapid increase in 
intracellular reactive oxygen species levels (Liu et al. 2005B). Moreover, 5F could also 
induce apoptosis in human colon cancer HT-29 cells. It was demonstrated that B-cell 
lymphoma protein 2 (Bcl-2) or Bcl-xL were over-expressed in HT-29 cells leading to 
promotion of NF-KB activity and reduction of 5F-induced apoptosis. Furthermore, IKBCX 
supper repressor, an NF-KB inhibitor, restored the apoptosis inducing ability of 5 F even 
cells transfected with Bcl-2 (Chen et al. 2004). Such finding indicated NF-KB related 
pathway could be one of the apoptosis mechanism induced by 5F. 
In cancer chemoprevention and chemotherapy, induction of apoptosis is a popular 
strategy by introducing the cancer drug either orally or injection. Since 5F can induce 
apoptosis as shown by many evidences, it can be employed as a potential apoptosis 
inducting drug in laryngeal cancer therapy. As mentioned in the previous section (1.2), 
HPV could promote anti-apoptosis. How 5F functions in HPV positive or negative 
laryngeal cancer cells is unknown. Moreover, NF-KB, one of 5F target in human colon 
cancer cells, is one of the most important apoptosis regulators. Because NF-KB activity 
was increased in laryngeal cancer (Du et al. 2003), its role in 5F-induced apoptosis 
might be pivotal. 
1.6 Objectives 
In this project, three laryngeal cancer cell lines, UMSCCl 1 A, UMSCC 12 and HEp-2, 
were employed. HEp-2 is HPV 18 positive while the others are HPV 18 negative. By 
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using these three cancer cell lines as models, two major objectives were investigated, 
including analysis of the apoptosis inducing effect of 5F in human laryngeal cancer cells 
with or without HPV 18 infection and study the role of N F - K B in 5F-induced apoptosis in 
laryngeal cancer cells accompanied with the evidence shown by N F - K B specific 
inhibitor, Bay (11-7082) (Chopra et al. 2008). 
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Chapter Two Materials and Methods 
2.1 Cell culture 
Two human laryngeal cancer cell lines (UMSCCllA and UMSCC12) were kindly 
provided by T Carey from the University of Michigan. They were cultured in Minimum 
Essential Medium (MEM, GIBCO-BRL, Carlsbad, CA) supplemented with 10% fetal 
bovine serum, lOOU/ml penicillin (GIBCO-BRL, Carlsbad, CA), lOO^g/ml streptomycin 
(GIBCO-BRL, Carlsbad, CA), at 37�C in a humidified atmosphere of 5% CO2 and 95% 
CO2. The culture medium was changed once every two days. 
Human laryngeal cancer cells, HEp-2 (American Type Culture Collection, ATCC), 
containing an integrated HPV 18 genome, were cultured in Dulbecco's Modified Eagle's 
Medium (DMEM, GIBCO-BRL, Carlsbad, CA) supplemented with 10% fetal bovine 
serum, lOOU/ml penicillin, 100|Lig/ml streptomycin at 37°C in humidified atmosphere of 
5% CO2 and 95% CO2. The culture medium was changed once every three days. 
2.3 Cell proliferation analysis 
3-(4，5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay is a 
colorimetric assay that measures the cell growth and determines the cytotoxicity of a 
toxic agent. The assay is based on the reduction of yellow MTT that is converted into 
deep blue formazan crystals by mitochondrial reductase from viable cells. The crystals 
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are impermeable to the cell membrane and so accumulate in viable cells. A 
solubilization solution, such as dimethylsulphoxide (DMSO), is added to dissolve the 
insoluble purple crystal solution. The absorbance of this colored solution is quantified by 
measuring its absorbance at a wavelength of 570nm by spectrophotometer. The 
absorption maximum depends on the solvent employed. 
The reducing reaction takes place in mitochondria when reductase is active. Therefore, 
the number of viable cells is directly proportional to the conversion of yellow MTT. By 
comparing the amount of formazan between the treatment group and control group, the 
effectiveness (and hence cytotoxicity) of an agent in causing cell death can be 
determined by generating a dose-response curve. 
In our experiment, cells (UMSCCllA, UMSCC12 and Hep-2) were seeded at the 
density of 5 x 10Vl00|Lil/welI in 96-well microtitration plates (NUNC) for 18 hours. A 
variety of concentrations of 5F (0.1% Dimethyl Sulphoxide (DMSO) (D2650, Sigma), 
3.125, 6.25, 12.5, 25, 50, 100 and 200)ig/ml), diluted by medium, were added and 
incubated for 24 or 48 hours after aspirating the old medium. Each group of 
concentrations were performed in triplicate wells and repeated three times. After 
different periods of incubation, the medium was aspirated, and then 100|il MTT (Sigma, 
St. Louis, MO) (diluted by phosphate buffered saline (PBS)) was added. The diluted 
MTT was added in each well and incubated for 3 hours at 37°C to allow viable cells to 
metabolize the MTT. The MTT was aspirated and the formazan crystals were dissolved 
by adding 1 OOfil/well DMSO. The absorbance was measured at a wavelength of 570nm 
with reference to a wavelength of 630nm with a spectrophotometer (VICTOR^TM 
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Multilabel Counter, PerkinElmer). Cell viability was presented as a percentage of the 
control group. 
2.3 Western Blotting 
Western Blotting involves several steps including protein extraction, protein 
quantification, gel electrophoresis, transferring protein, immunoblotting and developing. 
2.3.1 Total protein extraction 
Cells (5 X 105) were detached by warm Trypsin-EDTA (GIBCO-BRL, Carlsbad, CA) 
from the culture dish and washed twice with ice-cold PBS, then resuspended in 100)LI1 
radioimmunoprecipitation buffer (RIPA buffer: IX PBS, 1% Nonident P-40 (NP-40), 
0.5% sodium deoxycholate, 0.1% Sodium dodecyl sulfate (SDS), pH7.6) together with 
the protease inhibitor cocktail (Roche) and lOOjiig/ml phenyl-methy-sulphonyl-fluoride 
(PMSF). The cells were then further disrupted and homogenized by passing them 20 
times through a 21 gauge needle and then incubating them at 4°C for 45 minutes. After 
centrifugation for 10 minutes at lOOOOrpm at 4°C, the supernatant was recovered and 
stored at 4°C. 
2.3.2 Nuclear and cytoplasmic protein extraction 
Cells (10^) were detached by warm Trypsin-EDTA from the culture dish and washed 
twice with ice-cold PBS. They were resuspended by up-and-down pipetting several 
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times with lOOjul IX Buffer A (10 x Buffer A stock: lOOmM 
'^-(2-hydroxyethyl)-1 -piperazineethanesulfonic acid (HEPES), pH7.9，lOOmM KCl, 
lOOmM (ethylene diamine tetraacetic acid) EDTA; 1ml IX Buffer A adding lO i^l 
lOOmM Dithiothreitol (DTT), lO i^l protease inhibitor cocktail, 40^1 10% NP-40) in a 
1.5ml eppendorf tube that was fixed in a rocking platform and shaken at ISOrpm for 10 
minutes in a cold room. After centrifugation for 3 minutes at 4°C at 15000 g, the 
supernatant (cytosolic fraction) was collected. The pellet was resuspended in 60|LI1 IX 
Buffer B (5X Buffer B stock: lOOmM HEPES, pH7.9，2M NaCl, 5mM EDTA, 50% 
glycerol; 147|il IX Buffer B adding 1.5)LI1 protease inhibitor cocktail and 1.5|LI1 lOOmM 
DTT) by vortexing it at the highest setting for 10 seconds or by using a Dounce 
homogenizer. Then the eppendorf tube was laid horizontally on the rocking platform and 
shaken at 200rpm for an hour. Finally, the nuclear fraction was obtained from the 
supernatant after centrifugation at 15000 g for 10 minutes at 4°C. 
2.3.3 Quantification of protein concentration 
The extracted protein (total protein, cytosolic protein and nuclear protein) was quantified 
by Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). A standard curve was generated by 
serial dilution of bovine serum albumin (BSA, R396E, Promega, Madison WI, USA) 
with different lysis buffer (total protein: RIP A, Cytosolic fraction: Buffer A, Nuclear 
fraction: Buffer B) ranging from 0 — 1.4|j.g/ml. The assay was performed in a 96-well 
plate (Nunc, Denmark) by adding 5|al of standard and sample proteins into each well 
with a triplicate setting. After pre-treatment of 25^1 Reagent A’ (1ml Reagent A and 
20|xl Reagent S) for about 20 seconds, each standard and sample protein was added to 
2 7 
200|xl Buffer B (dye reagent). After 15 minutes of incubation at room temperature, the 
protein concentration was determined by measuring the absorbance at a wavelength of 
595nm with a spectrophotometer (Fluo Star Galaxy, BMG Labtechnologies Pty. Ltd). 
2.3.4 Sodium dodecyl sulfate - polyacylamide gel electrophoresis (SDS-PAGE) 
and protein transfer 
An aliquot of 25|Lig total protein (cytosolic protein: 30|Lig, nuclear protein: 10|Lig) was 
mixed with 6X SDS loading buffer (350mM Tris-HCl pH6.8, 600mM DTT, 30% 
glycerol, 0.012% bromophenol blue) and denatured by boiling for 5 minutes at 99°C. 
The denatured protein and protein marker (Full Range Rainbow Recombinant Protein 
Molecular Weight Marker, GE Healthcare) were resolved by SDS-PAGE 
electrophoresis. 
After electrophoresis, the gel was equilibrated for 5 minutes with cold transfer buffer 
(25mM Tris，192 mM Glycine, 20% methanol, pH8.3). The proteins were then 
transferred onto a Nitrocellulose membrane by using a Bio-Rad Mini Trans-Blot cell. 
The transfer sandwich was packed with sponge on the bottom half of a plastic cassette 
using filter paper, protein gel, filter paper and sponge again. Protein larger than 65kDa 
was transferred for 120 minutes, while protein smaller than 65kDa was transferred for 
90 minutes at 1OOV at room temperature. To optimize the transfer condition, the transfer 
tank was surrounded by ice to slow down the increase of current. After transfer, the 
membrane with proteins was washed with TBST (20mM Tris-Cl, 137mM NaCl, 0.1% 
Tween-20, pH7.6) buffer for 5 minutes before immunoblotting. 
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2.3.5 Immunoblotting 
Membranes were incubated with 5% non-fat milk in TBST for 2 hours at room 
temperature prior the incubation with diluted primary antibodies at 4°C overnight. After 
washing with TBST three times in 1 Ominutes, the membranes were incubated with 
corresponding secondary antibodies diluted with 2% non-fat milk in TBST for 2 hours at 
room temperature. Once again, the membranes were washed with TBST three times in 
1 Ominutes. Chemiluminescent was developed by adding ECL or ECL plus reagent kit 
(Amersham Life Science Ltd., Buckinghamshire, UK) and exposed to X-ray films. 
2.4 N F - K B Luciferase Assay 
To study the transcriptional activity of NF-KB, a genetic reporter assay was applied in 
our model. Firefly Luciferase assay was employed, firstly because its reporter activity is 
available immediately on translation. Secondly, the assay sensitivity is high due to its 
light production having the highest quantum efficiency for chemiluminescent reaction 
with no background luminescence is found in the host cells. Thirdly, the measurement 
can be done within a few seconds. 
In our experiment, pNF-icB Luciferase plasmid (generously provided by Professor 
Vivian Lui, Department of Clinical Oncology, the Chinese University of Hong Kong) 
was transiently transfected into three laryngeal cancer cell lines: UMSCCl lA, 
UMSCC12 and HEp-2. In the pNF-KB Luciferase plasmid (clone map attached in 
appendix), 5 times repeat NF-KB responsive elements (GGGGACTTTCC) were cloned 
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into a pLuc-MCS vector which encodes Firefly Luciferase. Once N F - K B was activated 
by TNF-a, it translocates into the nucleus and binds to N F - K B responsive elements on 
the vector. The translated Firefly Luciferase protein, a monomeric 61kDa protein, 
catalyzes luciferin oxidation which generates high intensity light that is constant and 
stable for at least 1 minute. 
To perform the transient transfection, Lipofectamine 2000 (Invitrogen，Carlsbad, CA) 
was employed and the experimental procedures were followed according to the protocol 
recommended by the manufacturer. Briefly, cells (cell no. of UMSCCl 1A:1.8 x 
lOVml/well, UMSCCl2: 2 x lOVml/well, Hep-2: 1.5 x lOVml/well) were seeded in a 
12-well culture plate (Coming, USA) for 18hrs before transfection. Ijig pNF-icB 
Luciferase plasmid and Lipofectamine 2000 in an optimized ratio (plasmid to 
Lipofectamine 2000 ratio: UMSCCl lA: 1:1.5，UMSCC12: 1:2, HEp-2: 1:3) were mixed 
with OPTI-MEM (Sigma, St. Louis, MO) for 5 minutes separately. The plasmid and 
Lipofectamine 2000 were then mixed by pipetting up-and-down and then incubated for 
20 minutes prior to being added to each well. After incubation for 5 hours, the cells were 
recovered and the transfection mixture replaced with by fresh medium (with 10% FBS). 
24 hours later, cells were treated with different concentrations of 5F in serum free 
medium for 2 hours. 20ng/ml TNF-a was added into the medium for 6hrs in an attempt 
to stimulate the N F - K B transcription activity. The reaction was stopped by removing the 
medium and washing the cells twice with ice cold PBS. 120|il lysis buffer (0.05% Triton 
X-100, lOOmM Tris-HCl，pH7.8，2mM EDTA, buffer components following the 
protocol of Professor Vivian Lui) was added into each well and the cells were extracted 
3 0 
by a cell scraper. After vortexing for 15 seconds, the lysate was stored at -80°C 
overnight for higher lysis efficiency. After centrifuging at 13000 rpm for 10 minutes at 
4•，the supematants were aspirated into a new tube. 20(il cell lysate together with 50|j.l 
Luciferase assay reagent (Promega, USA) were mixed in a 96-well plate and the light 
intensity was measured by a spectrophotometer (VICTOR^TM Multilabel Counter, 
PerkinElmer). To normalize the Luciferase assay, the cell lysate was subjected to protein 
quantification as mentioned in the previous part. Each assay was performed in triplicate 
in each experiment and repeated three times. 
2.5 Annexin V apoptosis assay 
In an attempt to detect 5F-induced apoptosis, Vybrant^'^ Annexin V- fluorescein kit 
(Molecular Probes, Eugene, OR) was employed in our study. 
Apoptosis, or programmed cell death, is controlled by an internally encoded suicide 
program, representing a critical role in normal development. Apoptosis is distinguished 
from necrosis by distinct morphological and biochemical features, including shrinkage 
of the cytoplasm and loss of membrane asymmetry, condensation and fragmentation of 
the nuclear chromatin. In normal viable cells, phophatidylserine (PS) is located on the 
cytoplasmic surface of the cell membrane. If the cell undergoes apoptosis, PS 
translocates from the inner plasma membrane to the outer leaflet, leading to the exposure 
of PS on to the external cellular environment. Such a characteristic feature provides us 
with a specific way to label an apoptotic cell and to determine the number of apoptotic 
cells. 
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Annexin V，a human anticoagulant, is a 35-36kDa Ca2+-depenclent phospholipid-binding 
protein that has a high affinity for PS. Annexin V labeled with a fluorophore or biotin 
can identify apoptotic cells by binding to PS exposed on the outer the leaflet. The 
V y b r a n t ™ Annexin V- fluorescein kit contains recombinant annexin V conjugated to 
Alexa Fluor 488 dye (a good spectral to fluorescein - FITC) and the red-fluorescent 
propidium iodide (PI) nucleic acid binding dye. PI cannot permeate viable and apoptotic 
cells, but can however stain necrotic cells with a red fluorescence by binding tightly to 
the nucleic acids in the cell. After staining a population of cells with annexin V and PI, 
apoptotic cells show green fluorescence (FITC) while dead cells show red (PI) and green 
fluorescence, and viable cells show little or no fluorescence. 
In this project, three laryngeal cancer cell lines (UMSCCl lA, UMSCC12, HEp-2) were 
treated with different concentrations of 5F (0.1% DMSO，50，75，lOO i^g/ml) for 16 or 24 
hours. Cells (UMSCCllA: 3.7 x 10^ UMSCCl2: 3.8 x 10^ HEp-2: 3 x 10^) were 
seeded in 6-well plates for 18 hours before treatment with 5F. After incubation for 
different periods, both detached and attached cells were collected by trypsization and 
centrifuged for 5 minutes at 2000 rpm. The cell pellet was then resuspended and washed 
three times with ice-cold PBS. For each sample, a master-mix solution, including lOOfil 
binding buffer (lOmM HEPES, 140mM NaCl，2.5mM CaCh, pH7.4)，5^1 Alexa Fluor 
488 Annexin V，2^1 of 100一ml PI working solution, was added to resuspend the cell 
pellet and then incubated for 15mins in the dark at room temperature. After the 
incubation period, 400fil of binding buffer was added and the sample kept on ice in the 
dark and analyzed by flow cytometry (FACScalibur, Becton Dickson, CA) and using 
Cell Quest software (Becton Dickinson, CA). 
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2.6 mRNA expression analysis 
To perform mRNA expression analysis, three steps were involved, including RNA 
extraction, reverse transcription (RT), and polymerase chain reaction (PGR). 
2.6.1 RNA extraction 
Total RNA of 1 x 10^  cells were extracted and purified by using PureLink™ 
Micro-to-Midi Total RNA Purification System (Invitrogen, CA). After the incubation 
period, the cells, either detached or attached to the culture plate, were collected by 
trypsinization and washed three times with ice-cold PBS. Cell pellets were then 
resuspended in 300fxl RNA lysis solution (1ml lysis solution added 10|li1 
2-mercaptoethanol) and mixed thoroughly with one volume of 70% ethanol by vortexing. 
All the samples were then transferred to the RNA Spin Cartridge and purified by 
following the protocol of the kit. The concentration and quality of the extracted RNA 
was determined by using a UV- spectrophotometer (Beckman Instruments, Inc., 
Fullerton, CA). 
2.6.2 Reverse Transcription 
Reverse transcription was performed according to the protocol of a Reverse 
Transcription System (Promega, Madison, WI). l|ig RNA was diluted into lOjul by 
adding RNase-free water and incubated at 70°C for 10 minutes and then placed on ice to 
cool down. 10|Lil of reagent from a master-mix solution was added into to each RNA 
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sample. For each reaction, the components of the master-mix solution include: 2\i\ 
Reverse Transcription lOX Buffer, 2[i\ dNTP mixture (lOmM), 4\i\ MgCh (25mM), l^il 
Random Primer, 0.5}xl Recombinant RNasin Ribonuclease Inhibitor (lu/fxl), 0.5 \i\ AMV 
Reverse Transcriptase (25u/|al). The reaction mixture was incubated at room temperature 
for 10 minutes before performing the RT reaction: 42°C for 60 minutes, 95°C for 5 
minutes. The cDNA product was incubated at 4°C. Through out the whole experiment, 
the cDNA and RNA stock was kept at -80°C. 
2.6.3 Polymerase Chain Reaction 
For each sample used to perform PGR, 2\x\ cDNA was added to \S\i\ master-mix 
solution which contains the following reagents: l.Sfil MgCl2 (25mM)(Promega), 0.5|al 
dNTP (lOmM), 1^1 Forward and Reverse Primer (lOpg/^il), 0.5|il Go Taq Fexi DNA 
Polymerase (Promega’USA)，2|xl 5X Green Go Taq Fexi Buffer (Promega，USA), ll.S^il 
dH20. The PGR mixture was firstly denatured by undergoing incubation at 94°C for 5 
minutes, and then 25 cycles were performed under the following cycling conditions: 
94°C for 30 sec, 55°C for 30 sec, ITC for 45 sec; extra time for extension: 72°C for 
10 minutes, and incubated at 4°C. The sequences of the primers that we used are listed 
below: 
Primer sequence of HPV 18 E6; 
Sense: 5' ATGGCGCGCTTTGAGGATCCA 3’ 
Anti-sense: 5' TTATACTTGTGTTTCTCTGCGTCG 3， 
Primer sequence of HPV 18 E7: 
Sense: 5' ATGTATGGACCTAAGGCACACT 3， 
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Anti-sense: 5' TTACTGCTGGGATGCACACCA 3’ 
The PGR products were separated by 2% agarose gel and calibrated by running with 
DNA MW marker lOObp ladder (Promega, Madison, WI). The ethidium bromide stained 
DNA was visualized by Gel Doc XR (Bio-Rad, Italy) and software Quality One. 
2.7 Antibodies 
Antibodies that were used are listed below: 
Antibody Manufacturer 
P65 Santa Cruz Biotechnology, USA 
P50 Santa Cruz Biotechnology, USA 
Lamin B Santa Cruz Biotechnology, USA 
P-tubulin Santa Cruz Biotechnology, USA 
p-actin Santa Cruz Biotechnology, USA 
Bax Santa Cruz Biotechnology, USA 
IKBCX Cell Signaling Technology, USA 
COX-2 Cayman, USA (kindly provided by prof. Lui) 
Thermo Scientific, USA 
Cyclin Dl (SP-4) 
(kindly provided by prof. Lui) 
BD, Bioscience, USA 
EGFR (activated) 
(kindly provided by prof. Lui) 
. . Cell Signaling Technology, USA 
Survivin 
(kindly provided by prof. Lui) 
Mouse IgG-HRP Santa Cruz Biotechnology, USA 
Goat IgG-HRP Santa Cruz Biotechnology, USA 
Rabbit IgG-HRP Santa Cruz Biotechnology, USA 
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Chapter Three Results 
3.1 Anti-proliferation effect of 5F on laryngeal cancer cells UMSCCl 1 A, 
UMSCC12 and HEp-2 cells 
We first investigated the effect of 5F on the growth of three laryngeal cancer cell lines: 
UMSCCl 1 A, UMSCC12, and HEp-2 (HPV 18 positive). Cell proliferation was 
measured by MTT assay after 24 and 48 hours of treatment. 
More viable cells were found in HEp2 cells (10% higher) than in UMSCCl 1A and 
UMSCCl2 cells after 24 hours of treatment at different 5F concentrations (Figure 1). 
The percentage of viable cells in UMSCCl lA was 65% at 50|ag/ml 5F and decreased 
sharply to 28% at 100|ig/ml. In UMSCCl2, the viable cell percentage was 65% at 
50|xg/ml and 36% at 100|ig/ml, while that in HEp-2 cells was 76% at SO i^g/ml and 45% 
at 100|ig/ml. After 48 hours of treatment, 5F showed a stronger inhibitory effect on the 
laryngeal cancer cells. But still, HEp2 was less susceptible to 5F, while UMSCCl lA 
and UMSCCl2 responded similarly to 5F. The percentage of viable cells in 
UMSCCl lA was significantly (P<0.05) lower than in UMSCCl2 and HEp-2 cells at 
50|ig/ml 5F at 48 hours. Our results show that 5F elicited a dose-dependent growth 
inhibition on all laryngeal cancer cell lines tested at 24 and 48 hours when compared to 
the control (0.1% DMSO). Through the dose-response curves at 24 and 48 hours, IC50 
values of laryngeal cancer cells were determined: 50|ig/ml for UMSCCl 1A and 
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Figure 1. 
5F inhibits cell proliferation in laryngeal cancer cell lines. UMSCCllA, UMSCC12 
and HEp-2 were treated with different concentrations of 5F (0.1% DMSO, 3.125, 6.25， 
12.5’ 25, 50, 100，200叩/ml) for 24 hours (A) or 48 hours (B). The MTT assay was 
performed as described in materials and methods. Values shown represent the mean of 
three separate experiments with each experiment performed in triplicate (* P < 0.05). 
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3.2 Suppression by 5F in HEp-2 of mRNA and protein expression levels in HPV 18 
E7 while the expression levels of HPV 18 E6 was not altered. 
Since HEp-2 carries HPV18, which promotes cell growth in cervical cancer (Fujii et al. 
2006), HPV 18 may account for the resistance to the anti-proliferation effect of 5F on 
HEp-2. HPV 18 encodes oncoproteins E6 and E7, which are responsible for viral 
replication, cell proliferation and for the prevention of host cell-mediated apoptosis. We 
postulated E6 and E7 may be responsible for the HEp-2 resistance to the 
anti-proliferation effect of 5F. Therefore, we investigated their steady-state mRNA and 
protein levels by semi-quantitative RT-PCR and Western blotting respectively after 5F 
treatment. It was found that neither the mRNA nor protein expression levels of E6 were 
altered after 5F treatment (Figure 2). In contrast, 5F suppressed both mRNA and protein 
expression levels of E7 in a time-dependent manner. Therefore, we suggest that the 
altered E7 oncoprotein levels in response to 5F may not be responsible for the HEp-2 
resistance to 5F. 
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Figure 2. 
5F down-regulated the mRNA and protein expression of HPV18 E7 but not the 
mRNA and protein expression of E6. HEp2 cells, which are positive for HPVl8, were 
exposed to 75|ig/ml 5F for different periods (0，12, 24，36 and 48 hours). Total RNA was 
extracted from 5F-treated cells and the full length of HPV 18 E6 and E7 were amplified. 
The HPV 18 E6 and E7 proteins were detected by Western blotting. The mRNA and 
protein expression levels of E6 were not altered, while that of E7 was down-regulated by 
5F in a time-dependent manner (A). The relative expression level of E7 mRNA and 
protein were quantified by densitometer (B) (* P < 0.05). 
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3.3 Quantification of 5F-induced apoptosis in laryngeal cancer cells by Annexin V 
assay 
It has been shown that 5F induces apoptosis in various cancers including colon cancer 
cells, thyroid cancer cells and gastric cancer cells (Chen, Liang 2004; Liu, Ng 2005; Liu, 
Chen 2005). Therefore, we further investigated whether apoptosis contributed to the 
5F-induced growth inhibition of laryngeal cancer cells. Annexin V-PI co-labeling assay 
was used to quantify the apoptotic cells induced by 5F in UMSCCl lA, UMSCC12 and 
HEp-2 cells. In the flow cytometry data obtained after the Annexin V labeling assay, the 
lower right quadrant (Ann V +ve/PI —ve) represents the distribution of early apoptotic 
cells (Figure 3，4 and 5) while the upper right quadrant (Ann V +ve/PI +ve) represents 
the late apoptotic and dead cells. In this experiment, only the early apoptotic cells in the 
lower right quadrant were counted. The apoptotic cells in the upper right quadrant were 
excluded because they may include necrotic cells. 
Following 5F treatments, apoptosis occurred in a dose-dependent manner in all the cell 
lines tested (Figure 3，4 and 5). After 16 hours of treatment with 50, 75 and 100|ig/ml, 
the corresponding percentages of apoptotic cells in UMSCCl lA were 9.05%, 10.16% 
and 11.11% respectively. Similarly, after 24 hours treatment, the percentage of apoptotic 
cells increased from 16%, 17.64% to 22.44% under the same concentration at 16hrs, 
indicating that the degree of apoptosis was more significant with longer incubation time. 
However, in HEp-2, the apoptotic cells induced by 16 hours treatment of 100|Lig/ml 5F 
were only 2% higher than the vehicle control. Although more cells underwent apoptosis 
following a prolonged incubation time (24 hours), the level of apoptosis in HEp-2 was 
4 0 
significantly lower than that of UMSCCllA (P<0.01) and UMSCCl2 under the same 
concentrations of 5F (Figure 6). Such differences might be due to the anti-apoptotic 
characteristic of HPV 18 in HEp2. Comparing the two HPV 18 negative cells, the 
percentage of apoptosis in UMSCCl lA was statistically higher (P<0.05) than that in 
UMSCCl2 when the dosage of 5F was 50 |xg/ml at either 16 or 24 hours. Our results 
demonstrated that apoptosis is induced by 5F in laryngeal cancer cells UMSCCl lA and 
UMSCCl2，but at a lower degree in HEp-2. 
3.4 Morphological changes in laryngeal cancer cells induced by 5F 
Changes in cell morphology by 5F were observed under the microscope. When 
compared with the control group, 5F caused more shrinkage and detachment of the 
laryngeal cancer cells (Figure 7). Such morphological changes represented some of the 
apoptotic characteristics in laryngeal cancer cells. The degree of such morphological 
variations was proportional to the concentrations of 5F added to the cells. The scale of 
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Figure 3. 
5F induced apoptosis of UMSCCllA cells in dose-dependent manner. UMSCCl 1A 
cells were exposed to 5F (0，50，75 and 100 ^ig/ml) for 16 or 24hrs, and then subjected to 
Annexin V flow cytometry analysis to determine apoptosis. 
4 2 
16hrs 24hrs 
- o - 、•！ 
"O. . . . . … 雄 、 ： . . 磁 、 . 
A 1 0 / ： .: • ； •. ： .::.‘.:;,、... . ： ••• I ： V • •• 
、•’ • \ N •V.O、... ，，，•、.•' •、【• •• • . • 
lV • • 10^  10� 10l 10^  103 10^  、^ 
50ug/ml 丨 . . . . 灘 . n .. .. ...: ” _ 
4 .•燃 i g M ^ ^ - 6.72+1.18% 
P11 
、！ 、^ 
75ug/ml ： ‘-.:。： ： ... -••• •. ...... 
10® 10^  io2 10® io4 ；。 VQ^ 10^  
PL1 FL1 
� 1 r � 1 
lOOug/ml ^ ： : . . : : • : : • • : : . 卿 : : _ 丨::,..::、..：:?::._. 
0 10' 10^  io3 �g Tyjwiffi^- \ FL1 0 10^  103 10^  FL1 
Figure 4. 
5F induced apoptosis of UMSCC12 cells in dose-dependent manner. UMSCC12 
cells were exposed to 5F (0，50，75 and 100 |xg/ml) for 16 or 24hrs, and then subjected to 




« ： . . ； ,:、<•:,; ‘ ； 缺 V�� : :‘ CO ’ • 
A 1 0 / ： •-.•••、：•.- • • ‘ • ： \ •：••： ... ‘ 
U.1/0 矜 .、：;•.工,.,,....~“ - -U' V-：-. 
”…^？^“^广…，、》…,卜丨….•,_‘b ^^o O1 10^  10^  10" 10^  loZ 10^  10^  FLI FL1 
、1 ： - 、 ！ 
“ 10^  10^  ° 10^  10^  10^  10^  FLI FLI 
、！ 1 • 、！ r 
75ug/ml�‘~•聰.._::,，..： ：〔參、:�:.纏 
10° ；o2 io3 10° 10^  10^  10" CI 1 Fl 1 
、！ —^— 、1 
looug/mi ： •.,〜.•., - ^ . ^ m m m 
° 10^  10^ 10-^  10'* ° 10^  10^ 10^ 10"* FLI FLI 
Figure 5. 
5F induced apoptosis of HEp-2 cells in dose-dependent manner. HEp-2 cells were 
exposed to 5F (0，50，75 and 100 |xg/ml) for 16 or 24hrs, and then subjected to Annexin 
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Figure 6. 
Comparison of 5F-induced apoptosis in cell line UMSCCllA, UMSCC12 and 
HEp-2. After exposure to different doses of 5F (0，50，75 and 100 }ig/ml) for 16hrs (A) 
or 24hrs (B), apoptosis was induced at different rates and magnitudes in the three cell 
lines (* P < 0.05, * * P < 0.01). 
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Figure 7. 
5F induced cell morphology changes in UMSCCllA, UMSCC12 and HEp-2 cell 
lines. The cells were incubated with different concentrations of 5F (0.1% DMSO, 50’ 75 
and 100|Lig/ml) for 24hrs. Cell morphology was observed by a Nikon OPTIPHOT-2 
fluorescence microscope at 200X magnification (Nikon, Tokyo, Japan) 
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3.5 Cleavage of poly (ADP-ribose) polymerase (PART) and pro-caspase-3 induced 
by 5F in UMSCCllA, UMSCC12 and HEp-2 cell lines 
To further investigate 5F-induced apoptosis in laryngeal cancer cells, Western Blotting 
was used to detect the cleavage of pro-caspase-3 and PARP, which are the hallmarks of 
apoptosis. On apoptosis, pro-caspase-3 is activated in order to cleave PARP, facilitating 
cellular disassembly. Cleavage of pro-caspase-3 and PARP appeared at 12 hours in 
UMSCCl lA (Figure 8). In UMSCCl2 and HEp-2 the activated caspase-3 and cleaved 
PARP were also detected at 24 hours. This indicates that 5F induced apoptosis as early 
as 12 hours in UMSCCl lA, 24 hours in UMSCCl2 and HEp-2. Densitometry analysis 
(Figure 9) showed that the relative level of cleaved caspase-3 and PARP increased with 
the 5F incubation time and peaked at 36 hours. 
3.6 Down-regulation of TNF-A-induced N F - K B subunit p65 and p50 nuclear 
translocations in UMSCCllA, UMSCC12 and HEp-2 by 5F 
The apoptosis inducing effect of 5F is known to be associated with the inhibition of 
N F - K B signaling in human colon cancers (Chen, Liang 2004) and the activity of N F - K B 
has been reported to be increased in laryngeal cancer tissue (Du, Chen 2003; Pan et al. 
2005; Kourelis et al. 2007). However, whether 5 F in laryngeal cancer acts on N F - K B is 
unknown. As N F - K B nuclear translocation is a crucial step for its signaling pathway, we 
analyzed the nuclear levels of N F - K B subunits p65 and p50 in 5F-treated UMSCCllA, 
UMSCCl2 and HEp-2. TNF-a was used to stimulate the cellular translocation of 
p65/p50. Western Blotting for Lamin B and p-tubulin were used as a reference indicator 
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of equal loading of the nucleus and cytoplasm protein fraction. The levels of Lamin B 
and p-tubulin were almost undetectable in the cytoplasm and nucleus indicating that 
there was no contamination in the fractions. In the absence of the stimulus, the basal 
levels of nuclear p65/p50 were reduced to 0.2 fold in the presence of 50|Lig/ml 5F in all 
laryngeal cancer cells (Figure 10). On stimulation by 20ng/ml TNF-a, the levels of 
nuclear p65 and p50 greatly enhanced in the nucleus but their levels in the cytoplasm 
were reduced, indicating the nuclear translocation of the two proteins. In UMSCCl 1 A, 
1.5 and 3 folds increase of nucleus p65 and p50 occurred respectively after TNF-a 
activation. In UMSCCl2，the level of nuclear p65 and p50 was drastically increased by 
3.2 and 4.5 folds respectively. In HEp-2, 6 and 26 folds of nuclear p65 and p50 
increments were observed. When cells were co-treated with TNF-a and different 
dosages of 5F, the p65 and p50 nuclear translocation was reduced by 5F in a 
dose-dependent manner. Interestingly, the reduced effect of p65 and p50 translocation 
by 5F in HEp-2 was weaker than in UMSCCl 1A and UMSCC12. 
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Figure 8. 
5F induced cleavage of pro-caspase-3 and poly (ADP-ribose) polymerase in 
UMSCCllA，UMSCC12 and HEp-2 cell lines. UMSCCllA and UMSCC12 were 
treated with 50|ig/ml 5F and HEp-2 with 75\xg/m\ 5F for different periods (0，12’ 24’ 36 
and 48 hours). Both attached and floating cells were collected and lysed to detect the 
apoptosis hallmarks, caspase-3 and poly (ADP-ribose) polymerase, by Western Blotting. 
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Figure 9. 
Densitometry analysis of cleaved caspase-3 and PARP in UMSCCllA, UMSCC12 
and HEp-2 cell lines. Table A, B and C respectively represent cleavage of PARP in 
UMSCCllA, UMSCCl2 and HEp-2. Table D, E and F represent cleavage of 
pro-caspase-3 in UMSCCl 1A，UMSCCl2 and HEp-2 respectively. 
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Figure 10.5F inhibits the TNF-a-mediated translocation of N F - K B subunits p65 and 
p50. UMSCCl 1 A, UMSCCl2 and HEp-2 cells were pre-treated with different dosages 
of 5F (50, 75 and 100 ^ig/ml) in serum free medium for 2 hours. Cells were then 
stimulated with 20ng/ml TNF-a for 20 min. The nuclear and cytoplasm proteins were 
isolated to detect p65 and p50 proteins. The relative expression level of the nuclear p65 
and p50 proteins in UMSCCl 1A (A), UMSCCl2 (B) and HEp-2 (C) are represented by 
the bar chart. (* P < 0.05) 
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3 .7 Dose-dependent inhibition of 5 F on NF-KB transcriptional activity measured 
by luciferase assay 
The effect of 5F on the N F - K B transcriptional activity was examined by luciferase assay. 
Laryngeal cancer cells were transiently transfected with pLuc-MCS plasmid (control 
vector containing minimal TATA box) or pLuc-NF-KB plasmid (containing five repeats 
of N F - K B response element in the promoter). The signal generated from the pLuc-MCS 
transfection was regarded as the background of the assay (Figure 11). Without any 
treatment, transfection of pLuc-NF-KB in laryngeal cancer cells generated higher 
luciferase activity than pLuc-MCS, indicating the basal NF-KB activation status in 
different laryngeal cancer cells. The luciferase activity generated by the basal N F - K B 
activity was regarded as a reference value for the other treatment. In the presence of 5F 
alone, the luciferase activity due to basal NF-KB activation was suppressed 0.2 fold. On 
stimulation by TNF-a, the luciferase activity was increased 3 folds, 16 folds and 2 folds 
in UMSCCllA, UMSCC12 and HEp-2 respectively. With 50|Lig/ml 5F pre-treatment, 
the TNF-a induced luciferase activity was significantly inhibited 3 folds in UMSCCl lA 
(P<0.05), 7 folds in UMSCCl2 (P<0.05), and 1.4 fold in HEp-2. Our results 
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Figure 11. 
5 F inhibited N F - K B luciferase activity in a dose-dependent manner in UMSCCllA 
(A), UMSCC 12 (B) and HEp-2 (C) cells. N F - K B responsive elements were cloned into 
a pLucMCS plasmid, which was transiently transfected into the cells for 24 hours. The 
transfected cells were cultured in serum free medium in the presence or absence of 5F 
for 2 hours, followed by 20ng/ml TNF-a for another 6hrs. On stimulation by TNF-a, 
p65/p50 bound to responsive elements on the plasmid and triggered the expression of 
luciferase which generated luminescence. The luciferase activity reflected the N F - K B 
transcriptional activity (* P < 0.05，** P < 0.01). 
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3.8 Partial inhibition of TNF-a induced IicBa degradation by 5F in UMSCCllA 
but not in UMSCC12 and HEp-2 
The induction of p65 and p50 nuclear translocation by TNF-a is known to involve the 
degradation of IicBa. We thus investigated whether 5F suppressed the degradation of 
IKBCC induced by TNF-a. We found that 50^g/ml 5F did not alter the basal expression 
level of IKBOI and that TNF-a stimulated the degradation of k B a (Figure 12) in 
laryngeal caner cells. When UMSCCl 1A cells were pre-treated with 5F for 2 hours, the 
level of iKBa was higher than that with TNF-a only. In contrast, the levels of IicBa in 
UMSCCl2 and HEp2 in response to TNF-a were not altered by pre-treatment with 5F. 
Our finding showed that 5 F suppressed TNF-a-induced NF-KB translocation by 
retardation of IicBa degradation in UMSCCllA, but not in UMSCCl2 or Hep-2. This 
suggests that 5 F can affect TNF-a-induced NF-KB translocation in laryngeal cancer cells 
through different mechanisms. 
3.9 Cell proliferation inhibition and apoptosis induction by Bay (11-7082) in 
laryngeal cancer cells 
Our results demonstrated 5F induced apoptosis and inhibited the nuclear translocation 
and transcription activity of NF-KB. However, whether the suppressed NF-KB activity in 
laryngeal cancer cells could result in apoptosis is unknown. To address this point, we 
used specific N F - K B inhibitor Bay (11-7082) to verify the effect of NF-KB inhibition on 
apoptosis induction in laryngeal cancers. 
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We found that Bay (11-7082) slowed down the cell proliferation rate of laryngeal cancer 
cells in a dose-dependent manner (Figure 13) after 24 and 48 hours of treatment. This 
confirmed that the inhibition of the NF-KB pathway by Bay (11 -7082) led to the 
retardation of cell proliferation. In the Annexin V assay, 26.05% (士 3%) UMSCCllA 
cells, 2% (±0.40/0) UMSCCl2 and 2% (士 0.8%) HEp-2 underwent apoptosis after 24 
hours of treatment with 10|aM Bay (11-7082) (Figure 14). Our results from Annexin V 
assay confirmed that inhibition of NF-KB activity resulted in laryngeal cancer cell 
apoptosis. However, the inhibition of the NF-KB activation induced a high level of 
apoptosis only in UMSCCl 1A cells, but not in UMSCCl2 or HEp-2 cells. 
3.10 Differential basal nuclear translocation of p65 and p50 in laryngeal cancer cell 
lines 
UMSCCllA showed a higher sensitivity to 5F or Bay (11-7082) treatments than 
UMSCCl2 and HEp-2. We believe that this could be due to the different basal levels of 
nuclear p65 and p50 in various laryngeal cancer cell lines. By Western blotting, both 
nuclear p65 and p50 were found to be diminished by the action of 5F. Even though the 
nuclear levels of p65 and p50 were decreased by about 20% in all laryngeal cancer cells 
tested after the 2-hour 5F treatment, the basal levels of nuclear p65 in the UMSCCl lA 
cell line was higher than that in UMSCCl2 and HEp-2 while the levels of p50 were 
similar in all three cell lines (Figure3.15). This difference indicates that the inhibition of 
N F - K B plays a more important role in apoptosis induction in UMSCCllA than in 
UMSCCl2 and HEp-2. Consistent with this idea, we have shown that 5F induces a 
higher degree of apoptosis and that Bay (11-7082) only induces apoptosis in 
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UMSCCl lA but not in UMSCC 12 or HEp-2. 
3 .11 5F regulation of N F - K B target gene expression 
N F - K B activation exerts its carcinogenic effects via transcriptional activation of its target 
genes. Cylin D1 is over-expressed in a variety of cancers and is responsible for the 
progress of the cell cycle from the G1 to the S phase (Polsky and Cordon-Cardo 2003). 
Similarly, COX-2 is also over-expressed in cancer cells and mediates cell proliferation 
(Chun and Surh 2004). The role of EGFR is important in cell proliferation and DNA 
synthesis (Nishi et al. 2003). Survivin, which belongs to the inhibitor of apoptosis 
protein (lAP) family, is a negative regulator of apoptosis by inhibiting caspase activation 
(Zucchini et al. 2008). Bax is a pro-apoptotic regulator and responsible for the 
permeabilization of the outer mitochondrial membrane (van Delft and Huang 2006). We 
thus examined the effects of 5F on the expression of these NF-KB-regulated gene 
products in laryngeal cancer cells by Western blotting. We successfully identified a 
number of N F - K B target genes that were altered by 5F in a time-dependent manner 
(Figure 16). These include proliferation-related genes (COX-2, EGFR and cyclin Dl), 
anti-apoptotic gene (survivin), and pro-apoptotic gene (Bax). 
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Figure 12. 
5F inhibited TNF-a-induced IicBa degradation in UMSCCl 1A but not in 
UMSCC12 or HEp-2 cells. UMSCCl lA (A), UMSCCL2 (B) and HEp-2 (C) cells were 
pre-treated with 50)a.g/ml 5F in serum free medium for 2 hours, and then stimulated by 
20ng/ml TNF-a for 15min. The protein was isolated and subjected to Western blotting 
analysis for IKBCX ( P < 0.05). 
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Figure 13. 
Anti-proliferation effect of Bay (11-7082) in UMSCCllA, UMSCC12 and HEp-2 
cell lines. UMSCCl lA, UMSCCl2 and HEp-2 cells were treated with different dosages 
of Bay (0.1% DMSO, 1.5625, 3.125, 6.25，12.5, 25 and 50uM) for 24 (A) or 48 (B) 
hours. Cell proliferation was determined by MTT assay. The MTT assay was performed 
as described in materials and methods. Values shown represent the mean of three 
separate experiments with each experiment performed in triplicate. (P < 0.05) 
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Figure 14 
Bay (11-7082) induced apoptosis in UMSCCllA. UMSCCllA, UMSCC12 and 
HEp-2 were exposed to lOuM Bay for 24 hours, and subjected to Annexin V flow 
cytometry analysis to determine apoptosis. Values shown represent the mean of three 
separate experiments. 
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Figure 16. 
5 F down-regulated the expression level of NF-KB target genes. UMSCCllA and 
UMSCC 12 were exposed to 50jLig/ml 5F and HEp-2 was exposed to 75|ig/ml 5F for 
different periods (0，12，24，36 and 48hrs). Identifiable NF-KB target genes were 
detected by Western blotting (A) Expression of cell proliferation regulators: cyclinDl, 
COX-2 and EGFR; (B) Expression of anti-apoptotic regulator: survivin and (C) 
Expression of pro-apoptotic regulator: Bax. 
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Chapter Four Discussion 
Herbal extract 5F is known to inhibit cell growth in several types of tumor. However, its 
effect on human laryngeal cancer cells has not been studied yet. Our results 
demonstrated that 5F can effectively retard the proliferation of laryngeal cancer cells in a 
does-dependent manner. And this inhibitory effect on proliferation was attributed to the 
5F-induced apoptosis. Furthermore, we demonstrated that 5F significantly suppressed 
the transcription activity of N F - K B via the blockage of N F - K B nuclear translocation. 
Specific N F - K B inhibitor, Bay (11-7082)，also gave similar effects on laryngeal cancer 
cell growth inhibition and apoptosis induction. In response to the 5F-suppressed N F - K B 
activity, the expression levels of NF-KB target gene products were also down-regulated. 
Herein, we showed that the down-regulation of N F - K B transcription activity was 
involved in 5F-induced apoptosis in laryngeal cancer cells. Our study provides evidence 
for 5F as an effective therapeutic agent for targeted therapy in laryngeal cancer cells. 
As apoptosis inactivation is common in tumors and contributes to carcinogenesis, 
apoptosis induction is thus one of the most obvious strategies for cancer therapy. It has 
been shown that the N F - K B signaling pathway and its downstream gene products are 
critical regulators of the apoptotic responses (Karin and Lin 2002). Constitutive 
activation of N F - K B is found to be a common feature in various human cancer cells 
including laryngeal cancer cells (Du, Chen 2003; Pan, Tao 2005; Pacifico and Leonardi 
2006). Nevertheless, the functional role of N F - K B in laryngeal cancer remains to be 
investigated. Here, through direct inhibition of N F - K B nuclear translocation by 5F, we 
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demonstrated that constitutive N F - K B activation is required for laryngeal cancer cell 
growth and apoptosis inhibition. 
5F induced apoptosis has been shown in human colon cells via down-regulation of the 
N F - K B activity (Chen, Liang 2004). Our results are consistent with previous findings in 
which 5 F suppressed the basal and TNF-a-induced NF-KB activity in laryngeal cancer 
cells (Figure 11). In the absence of stimulus, N F - K B is sequestered into the cytoplasm by 
binding with IicBa in the classical pathway. Therefore, the basal N F - K B activity 
observed in our luciferase assays was due to the constitutive basal activation of N F - K B 
in laryngeal cancer cells. This was further confirmed by the presence of nuclear p65 and 
p50 protein in the absence of stimulus (Figure 15). Upon stimulation with TNF-a, IKBCI 
is phosphorylated by the IKK complex and then degraded subsequently. Since nuclear 
translocation is the last step of the NF-KB activation cascade preceding 
NF-KB-dependent transcription, blocking of N F - K B nuclear translocation is a major 
target for N F - K B inhibitors. IKBCI is the commonest targets of numerous N F - K B 
inhibitors acting on N F - K B or its up-stream signaling pathway. The inhibitory action of 
these inhibitors on IKBCI degradation often results in an increase in the level of IKBOL 
Bay (11-7082) is an irreversible inhibitor of IKBCX phosphorylation and the subsequent 
proteasomal degradation. Thereby, Bay (11-7082) sequesters N F - K B in its inactive state 
in the cytoplasm and prevents the activation of N F - K B downstream signaling. We 
demonstrated that 5 F inhibited the activation of N F - K B by partially suppressing the 
degradation of IicBa in UMSCCl lA. The inactivation of N F - K B by 5 F was independent 
of iKBa degradation in UMSCCl2 and HEp-2 (Figure 12). Rather 5F might inhibit 
N F - K B activation in UMSCCl2 and HEp-2 by masking its nuclear translocation signal 
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or blocking the nuclear transporter of NF-KB. In fact, there are evidences showing that 
same NF-KB inhibitors can act on different points along the NF-KB pathway in different 
cells (Karin et al. 2004). Sulphasalazine, a non-steroid anti-inflammatory drug, 
suppresses NF-KB activation via blocking the phosphorylation and degradation of IicBa 
in response to stimuli. However, 5-amino-salicylic acid, an oral administrated derivative 
of sulphasalazine, was shown to block NF-KB activation through inhibiting IKK-A and 
IKK-P kinase activity (Wahl et al. 1998; Yan and Polk 1999). Since the permeability or 
uptake of 5F may be cell line specific, its inhibition mechanism in UMSCCl2 and 
HEp-2 needs to be further investigated. 
Our experiments showed that 5 F induced apoptosis and inhibited the NF-KB activity in 
laryngeal cancer cells. However, this did not mean that NF-KB inhibition in laryngeal 
cancer cells induced apoptosis. To address this, we studied the effects of Bay (11-7082) 
on the N F - K B activation and the apoptosis induction in laryngeal cancer. Our MTT 
assays showed that the cell proliferation rate was retarded in the presence of 10|j,M of 
Bay (11-7082). Annexin V assay showed that apoptosis was induced by Bay (11-7082) 
(10|LIM) in U M S C C L L A . Given that Bay ( 11 -7082) specifically inhibits the NF-KB 
activity, these results indicated that the effects of Bay (11-7082) in laryngeal cancer cells 
were attributed to the inhibition of NF-KB function. Therefore, we conclude that NF-KB 
is involved in the 5F-induced apoptosis in laryngeal cancer cells. Since NF-KB is a 
multi-fiinctional regulator for cell proliferation and apoptosis, our findings further 
support that the perturbation of NF-KB function is a potentially useful therapeutic 
strategy for laryngeal cancer treatments. 
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We also found it interesting that Bay (11-7082) only significantly induced apoptosis in 
UMSCCl lA but not in UMSCCl2 and HEp-2. Indeed, in other cancers, mere inhibition 
of N F - K B is insufficient for inducing apoptosis (Karin 2006). We believe that the 
differential levels of basal NF-KB activation in various laryngeal cancer cells may 
contribute to the response differences to 5F in UMSCCllA, UMSCC12, and HEp-2. 
UMSCCl 1A exhibited a relatively higher constitutive N F - K B activity than that in HEp-2 
and UMSCCl2 (Figure 15). This indicated that N F - K B played a more important role in 
cell survival in UMSCCllA than that in UMSCCl2 and HEp-2. Similar situation has 
been reported by Angela A et al (Van Waes et al. 2005). Bortezomib, a novel 
proteasome inhibitor, suppresses a panel of HNSCC cell lines (including UMSCCllA, 
-1 IB) via inhibiting N F - K B activation with different sensitivity. However, the cell lines 
with low constitutive N F - K B activity were more resistant to bortezomib while those with 
high activity such as UMSCCllA and UMSCC 1 IB are more sensitive to bortezomib. 
On the other hand, it is noticeable that the higher constitutive N F - K B activity in 
UMSCCl 1A might be due to the relatively lower expression level of IKBCX (Figure 12). 
By comparing the finding from the treatment of 5F and Bay (11-7082)，we suggested 
that 5F induced apoptosis in laryngeal cancer cells involving other mechanisms in 
addition to N F - K B signaling pathway. 
Other than low constitutive N F - K B activity, the presence of HPV 18 may also contribute 
to the resistance to 5F for inducing apoptosis in laryngeal cancers. We found that HEp-2 
was more resistant to 5F than that in UMSCC 12. Hep2 is a HPV 18 positive cell line. 
Two cooperative oncoproteins E6 and E7 are encoded in the genome of HPV 18. E6 is 
responsible for cancer progression whereas the function of E7 is primarily for inducing 
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transformation (Song et al. 2000; Scheffner and Whitaker 2003). The small interfering 
RNAs (siRNAs) targeting E6 and E7 inhibits the growth of cervical cancer cells (Fujii et 
al. 2006). Suppression of E6 and E7 by antisense RNAs also significantly induces 
apoptosis in HeLa cells (Sima et al. 2007). Therefore, E6 and E7 are essential to the 
growth of human HPV-positive laryngeal cancers. Furthermore, the complex 
cooperation between E6 and E7 is essential for malignant transformation (von Knebel 
Doeberitz et al. 1988; zur Hansen 1994). Yamato et al reported that E6-specific 
suppression alone induced more apoptosis than the E6 and E7 co-suppression in HPV 18 
positive cervical cancer cells (Yamato et al. 2006). It is known that E7 inactivates cell 
cycle regulators like pRb in order to up-regulate genes for Gl/S transition and DNA 
synthesis. Moreover, E7 also causes the up-regulation of pro-apoptotic genes, such as 
c-Myc, Bak and p53 (Askew et al. 1991). However, in HEp-2, the E6 can rescue the 
cells from cell death by binding with these pro-apoptotic proteins for subsequent 
degradation (Gross-Mesilaty et al. 1998; Thomas and Banks 1998). Therefore, it is 
conceivable that without E6 co-expression, E7 can induce cell death by activating 
pro-apoptotic genes. On the other hand, suppression of E7 may induce cell growth arrest 
rather than cell death. Here, we demonstrated that 5F suppressed the mRNA and protein 
expressions of E7 whereas the expression of E6 was not altered. However, the reduced 
E7 expression by 5F did not enhance apoptosis significantly in HEp-2, when comparing 
with UMSCC 12. This might be due to the fact that the SF-induced E7 reduction was too 
subtle and the unaltered E6 level still exerted a significant anti-apoptotic effect. To 
address the apoptotic roles of E6 and E7 in laryngeal cancer cells, we suggest to evaluate 
the effects on apoptosis after silenting both genes in HEp-2, or introducing them into 
HPV-negative laryngeal cancer cells like UMSCCl 1A and UMSCC 12 in future. 
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NF-KB regulates both cell proliferation and apoptosis via its different target genes. After 
addressing the inhibitory effect of 5F on the NF-KB nuclear translocation, we then 
showed that 5F down-regulated a number of NF-KB known target genes in laryngeal 
cancer cells such as proliferation-related (COX-2, EGFR and cyclin Dl), anti-apoptotic 
(survivin), as well as pro-apoptotic genes (Bax). Expression of COX-2, EGFR and 
survivin has been shown to have value in predicting prognosis in laryngeal squamous 
cell carcinoma (Pan, Tao 2005; Marioni et al 2006; Wei et al. 2008). Increasing 
expression of survivin accompanied with laryngeal papilloma malignancy (Poetker et al. 
2002). The cell cycle and differentiation regulator EGFR is over-expressed in laryngeal 
papillomas and cultured papilloma cells (Johnston et al. 1999). Constitutive activation of 
NF-KB has also been shown in laryngeal papillomas and HPV-positive laryngeal cancers 
(Vancurova et al. 2002; Du，Chen 2003). Up-regulation both of COX-2 and NF-KB has 
been shown to be a feature of laryngeal carcinogenesis (Pan et al. 2005; Kourelis et al. 
2007). Given that NF-KB up-regulates COX-2, which then activates EGFR signaling 
(Sarkar and Li 2008), down-regulation of COX-2 and inactivation of EGFR via NF-KB 
inhibition can be used synergistically for killing cancer cells. Also, inhibition of NF-KB 
can lead to the suppression of survivin and EGFR and then prevents the malignant 
transformation of laryngeal papillomas. Therefore, our observation of the C0X2, 
survivin and EGFR down-regulation by 5F may be worthy for future development of 
laryngeal papilloma treatments. 
NF-KB signaling pathways have various effects on laryngeal carcinogenesis. It becomes 
one of the most attractive targets for cancer prevention and therapy. Here, we have 
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demonstrated that an herbal extract 5F effectively inhibits the growth of laryngeal cancer 
cells via induction of apoptosis. Moreover, the suppression of N F - K B activity by 5 F 
subsequently inhibits the expression of the NF-KB target genes responsible for cell 
proliferation and apoptosis. Our results implicate that 5F is a new potent anti-tumor 
agent for laryngeal cancers by targeting its N F - K B signaling pathway. 
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